Business Context and Reporting Period
This Form 8-K reports on events occurring on April 20, 2026, regarding First Tracks Biotherapeutics, Inc. (the "Company"). On this date, AnaptysBio, Inc. completed a pro rata spin-off of the Company to its shareholders. Simultaneously, the Company completed a private placement of common stock. The Company is a biotechnology firm focused on developing therapeutics for autoimmune and inflammatory diseases, including clinical-stage programs for rosnilimab, ANB033, and ANB101.
Key Financial Metrics and Capital Structure
- Private Placement Proceeds: The Company issued 5,791,478 shares and the Selling Stockholder (EcoR1 Capital Fund Qualified, L.P.) sold 4,705,575 shares at a purchase price of $13.81 per share.
- Cash Allocation: Under the Separation and Distribution Agreement, First Tracks Biotherapeutics received $100.0 million in cash and cash equivalents from AnaptysBio.
- Equity Issuance: 29,100,802 shares of Common Stock were issued to AnaptysBio in consideration for the transfer of the biopharma business entities.
- Future Milestone Rights: The Company retained rights to receive up to $35.0 million in milestone payments under the Vanda Collaboration for future regulatory approvals and sales.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or operating margin figures for the Company as a standalone entity for a reporting period.
Material Changes and Corporate Actions
- Spin-Off Completion: The Company separated from AnaptysBio. AnaptysBio retained the "Royalty Management Co. Business" (including Jemperli and imsidolimab royalties), while First Tracks Biotherapeutics retained the biotechnology development business.
- Asset and Liability Transfer: First Tracks Biotherapeutics assumed liabilities related to its business operations post-spin-off, while AnaptysBio retained liabilities related to its pre-spin-off operations and the Royalty Management business.
- Executive Appointment: Ajim Tamboli was appointed Chief Financial Officer effective April 20, 2026.
- Corporate Governance: The Company adopted an Amended and Restated Certificate of Incorporation and Bylaws effective upon the spin-off.
Management Commentary and Agreements
- Transition Services: A Transition Services Agreement was executed, under which First Tracks Biotherapeutics will provide services (digital technology, HR, finance, etc.) to AnaptysBio for up to two years to ensure an orderly transition.
- Indemnification: Mutual indemnification provisions were established between the Company and AnaptysBio regarding liabilities allocated to each party and breaches of the separation agreements.
- Registration Rights: A Registration Rights Agreement was entered into with private placement investors, requiring the Company to file a registration statement for the resale of shares within 45 days of the distribution date.
- Executive Compensation: The new CFO, Mr. Tamboli, received an initial annual base salary of $516,000, a target cash bonus of up to 40%, and equity awards valued at $2,550,000.
Investor Verification Checklist
- Verify the final cash balance of $100.0 million received from AnaptysBio and the total proceeds from the private placement.
- Review the specific terms of the Transition Services Agreement to understand ongoing operational dependencies on AnaptysBio.
- Confirm the status of the $35.0 million potential milestone payments from the Vanda Collaboration and the conditions required to trigger them.
- Examine the Separation and Distribution Agreement for any contingent liabilities or delayed asset transfers that could impact future financial statements.
- Monitor the filing of the registration statement for the private placement shares as required within 45 days of April 20, 2026.